Blogs

Be the first person to recommend this.
By Dr. Navneet Majhail, ASTCT President Thank you for the tremendous response to my first column as ASTCT President . I was impressed by the number of people who actually read it. The feedback was mostly positive – well, the only complaint was that I did not share a photo of Caesar! I did get a lot of helpful advice. And yes, I have started eating my veggies!! @BldCancerDoc advice for our new ASTCT President Dr Navneet Majhail #ASTCT 1. Prepare your newsletter way in advance 2. Eat your veggies. 3. Remember it’s only 12 months 4. You have good company use them 5. Delegate delegate and delegate Thanks for serving sg — sergio giralt (@sgiraltbmtdoc) ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Foundation for the Accreditation of Cellular Therapy Publication of the FACT Common Standards, Second Edition Congratulations to Dr. Paul Eldridge, FACT Standards Chair, and the FACT Common Standards Steering Committee on publishing the Second Edition FACT Common Standards for Cellular Therapies on March 15, 2019. The Standards will become effective on June 15, 2019. Committee Overview The Second Edition FACT Common Standards Steering Committee is comprised of 12 representatives who worked for 23 months on the development of the Standards. Everyone’s commitment, expertise, and experience is invaluable ...
0 comments
Be the first person to recommend this.
ASTCT’s Outreach on CAR-T The Centers for Medicare and Medicaid Services (CMS) requested comments on their Proposed Decision Memo for Chimeric Antigen Receptor (CAR-T) T-cell therapy. ASTCT submitted comments to the agency prior to the March 17 deadline. The public comment period is closed and we expect the final coverage determination to be released no later than May 17. ASTCT’s comments can be viewed here . The proposed National Coverage Analysis would require Medicare to cover the therapy nationwide when it is offered in a CMS-approved registry or clinical study, in which patients are monitored for at least two years post-treatment. ASTCT emphasized ...
0 comments
Be the first person to recommend this.
Registration is now open for April’s Online Journal Club. Reserve your seat for this webinar through the following link and please share to all that may be interested: https://attendee.gotowebinar.com/register/6146227515136446467 Dr. Mollie Beck will highlight an in-depth review regarding the article "Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma" . The goal of these journal clubs will be to provide education and more in-depth review of literature related to the field of stem cell transplantation and cellular therapy and will be provided a few times a year. Beck is currently completing her PGY2 Hematology/Oncology ...
0 comments
Be the first person to recommend this.
Long before the TCT Meetings of ASBMT and CIBMTR became what it is today, it was just a small meeting of friends during a ski trip. There wasn’t a name to those first few meetings. More than 10 years before the “official” meetings would kick off—then known as the Tandem Meetings—a group of physicians and researchers met to discuss emerging BMT and cellular therapies. Among them was Olle Ringdén, MD, PhD. In 1980, Ringdén hopped on a plane from Sweden—his home country—to Keystone, Colorado. He was encouraged to attend by renowned physicians Robert Gale, MD, PhD; and Richard Champlin, MD. “I had started a new center in Sweden,” Ringdén recalled. “It was ...
0 comments
Be the first person to recommend this.
The ASTCT Survivorship Special Interest Group (SIG) had yet another successful annual meeting during the TCT Meetings in Houston, Texas. The meeting growth underscores the growing interest in discussing the survivorship and late effect needs of hematopoietic stem cell transplant survivors and their caregivers. The SIG was fortunate to have patient stakeholders who attended the meeting, provided input and insight, and discussed the important role of engaging patients and caregivers in ongoing efforts focused on survivorship care.   The meeting began with brief reports from collaborating groups including the Palliative and Supportive Care SIG and the newly established ...
0 comments
Be the first person to recommend this.
ASTCT submitted comments on the CMS National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy last week. The public comment period has closed, and we expect the final coverage determination to be released no later than May 17. To read the comments, click here. ASTCT expressed concern that the coverage policy as proposed would limit patient access and recommended that the agency finalize a coverage policy that leverages existing registry reporting rather than coverage with evidence development (CED). Our comments suggested ways to revise the policy to protect patient access to approved CARs and those likely to be approved in the next five ...
0 comments
Be the first person to recommend this.
An updated set of CAR-T resource slides are now available to ASBMT members and non-members. These act as a resource to anyone in the cellular therapy field. The slides, created by the CAR-T Working Group, cover everything from the basics of immunology to managing neurotoxicity in CAR T patients. Hopefully by releasing the slides, members and non-members alike can utilize this important slide library and continue to improve the quality of care for patients around the worl
0 comments
Be the first person to recommend this.
Leading off this month are two big announcements for our policy and advocacy work going forward. First, as detailed here , we recently announced we're changing our name to the American Society for Transplantation and Cellular Therapy (ASTCT). We are also excited to welcome our newly appointed Director of Government Relations, Alycia Maloney. Maloney will lead ASBMT in our renewed commitment to advancing smart and patient-centered policy in the realm of transplantation and cellular therapies, and we look forward to a productive future under her policy leadership. For details on Alycia’s background, please see our official announcement here . As mentioned ...
0 comments
Be the first person to recommend this.
The American Society for Blood and Marrow Transplantation (ASBMT), newly named the American Society for Transplantation and Cellular Therapy (ASTCT), has carefully reviewed the recently released National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers and is in the process of developing comments for the Centers for Medicare and Medicaid Services (CMS).   The newly formed Government Relations Committee held its inaugural meeting at TCT last week and is providing guidance on a response to the NCA.  The agency will finalize its coverage policy to take effect in May.  Our members have been actively engaged in the research and ...
0 comments
Be the first person to recommend this.
Created by the ASBMT Board of Directors because of concerns that clinical fellowship programs don't adequately cover the principles of research and how to take findings from the laboratory to the clinic, this course helps close the gap by addressing those deficiencies. Join ASBMT on July 10 - 14 in Park City, UT. In the past, attendees have praised the CRTC as a wonderful opportunity to learn from and connect with others in the field of cellular transplantation.  If interested, please send your application and all required materials to Anna Hawkshead at  ahawkshead@asbmt.org  no later than March 15, 2019 at 11:59 PST
0 comments
Be the first person to recommend this.
ASBMT has recently formed three new SIGs: The Social Work SIG, the Women and Underrepresented Minorities SIG,and the Biobehavioral Research SIG. The Social Work SIG formed in order to further integrate social work into the multidisciplinary HCT team and provide an avenue for collaboration and the advancement of psychosocial health research. Our hope is to create an environment that will assist transplant/cell therapy social workers to grow their professional skills within our social work organization and our interdisciplinary collaborations within ASBMT to further the clinical use and position of social work with this very unique patient population. Meanwhile, ...
0 comments
Be the first person to recommend this.
This month we have a few special features with brief drug information updates highlighting important basics and monitoring parameter for gilteritinib, glasdegib, and venetoclax!  In this month’s literature updates, results from the NiCord ex-vivo expansion, BEAM vs BuCyVP16, outcomes in pediatrics with partially T-cell depleted grafts, and more! Please review new drug updates here: Gilteritinib Glasdegib Venetoclax Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that ...
0 comments
Be the first person to recommend this.
Mikaela VanMoorleghem, Education and Training Coordinator,   Foundation for the Accreditation of Cellular Therapy FACT EVENTS AT THE 2019 TCT MEETINGS WERE A SUCCESS! FACT hosted several popular events at the 2019 TCT | Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR in Houston, Texas. Over 150 people joined FACT on February 19 for the Cellular Therapy Inspection and Accreditation Workshop, which included major topics such as building quality into clinical immune effector cell programs, risk evaluation and mitigation strategies, using the Tracer Methodology to assess compliance with standards, common citations, reviewing clinical outcomes, ...
0 comments
Be the first person to recommend this.
By Dr. Navneet Majhail, ASBMT President  I was among the enlightened when I began hematology-oncology fellowship, since I had already decided on BMT as my career path. I was so determined to train at one of the meccas of transplantation that I was not fazed by the sub-zero temperature that fateful day in December when I interviewed at the University of Minnesota (thankfully, my wife first saw the Twin Cities in summer and it was too late by the time she experienced her first Minnesota winter). My first order of business as a fellow, before learning how to spell “trastuzumab,” was to sign up as an ASBMT member-in-training. Ever since, I have eagerly looked ...
0 comments
Be the first person to recommend this.
The American Society for Blood and Marrow Transplantation (ASBMT) , a professional society dedicated to advancing the science and clinical care for patients who require blood and marrow transplants, today announced it has changed its name to the American Society for Transplantation and Cellular Therapy (ASTCT) in recognition of the rapid shift toward cellular therapies in this field of medicine. The ASTCT name will better reflect the organization’s commitment to serving as the professional home and community for healthcare providers, researchers, and other professionals who are dedicated to cures involving blood and marrow transplantation and cellular therapies. ...
0 comments
Be the first person to recommend this.
Dear 2019 TCT Pharmacists Conference Attendee: On behalf of the 2019 TCT Pharmacists Conference Program Planning Committee, thank you for registering to attend our educational conference. This email will provide additional details pertaining to the conference and associated activities. Pharmacy Conference Location and Reception The 2019 TCT Pharmacists Conference will be held in the Hilton Ballroom of Americas, Room FC on Friday, February 22 and Saturday, February 23. Please join us for the Pharmacy Reception and Awards Presentation on Friday, February 22 from 6:00-8:00 PM (local time) in the Hilton Ballroom of Americas, Room FC. Registration for ...
0 comments
Be the first person to recommend this.
Today, the Centers for Medicare and Medicaid Services (CMS) released the proposed decision memo for the National Coverage Analysis (NCA) for CAR T-cell therapy. The proposal, found here , articulates how CMS would cover the advanced cancer therapy. We are in the process of reviewing the proposal and will be sending a second communication with a brief summary and draft talking points that can be utilized in your individual or organization’s response. ASBMT and other interested organizations have 30 days to review and comment.  CMS will issue final decision no later than 60 days after the conclusion of the 30-day comment period. ASBMT will be developing its ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Coordinator Foundation for the Accreditation of Cellular Therapy FACT Inspectors are Invited to Social Hour during TCT Meetings In honor of their dedication and service provided to the cell therapy community, FACT Inspectors are cordially invited to attend the FACT Inspector Social Hour on Friday, February 22, 2019 at the Hilton Americas-Houston Hotel, Room 335B from 5 pm – 6 pm. Light hors d'oeuvres and cocktails will be provided. -- International Delegates of the TCT Meetings Invited to Attend Special Session --  FACT International Accreditation The Foundation for the Accreditation of Cellular ...
0 comments
Be the first person to recommend this.
The discovery and development of chimeric antigen receptor T cells (CAR-T) cells for cancer immunotherapy has led to a paradigm shift in cancer management. Many professional medical societies have been closely involved in both the research and clinical aspects of CAR-T cells, however, ASBMT has taken a leadership role in various avenues of CAR-T cells including the society’s initiatives in health policy, clinical management and research. Recently, the ASBMT issued a position statement on grading of cytokine release syndrome (CRS) and neurological toxicity due to immune effector cells. Subsequently, the society released a statement on the clinical aspects of ...
0 comments